A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy

Trial Profile

A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 27 Mar 2017 Planned End Date changed from 1 Jun 2018 to 30 Aug 2019.
    • 27 Mar 2017 Planned primary completion date changed from 1 Jun 2018 to 30 Aug 2019.
    • 17 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top